DDIT3 and diffuse large B-cell lymphoma: Consistent with the outcome of ABC-DLBCL, patients with mTORC1 active DLBCL who are treated with R-CHOP have an unfavorable outcome compared to those with mTORC1 inactive DLBCL (negative p-S6 staining) who show a strikingly long OS (60 months) (86).